 |
 |
| December 30, 2009 |
Proteonomix |
 |
Proteonomix, Inc. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events EDGAR Online |
 |
On December 29, 2009, Joel Pensley, a director of the Registrant, resigned from the Board of Directors for health reasons. Mr. Pensley's position on the Board was filled by the appointment of Roger Fidler on December 29, 2009. As at the date of this Form 8-K there is no plan to appoint Mr. Fidler to any committees of the Board of Directors. No compensatory arrangement has been made between Mr. Fidler and the Registrant... |
|
| Read Full Story > |
|
 |
| February 10, 2009 |
Proteonomix |
|
Proteonomix, Inc. (PROT) Announces Definitive Agreement for Sale of Its Stem Cell Derived Cosmeceutical Products With Two Companies Headquartered in China |
|
MOUNTAINSIDE, NJ--(MARKET WIRE)--Feb 10, 2009 -- Proteonomix, Inc. (Other OTC:PROT.PK - News) announces that it and its subsidiary, Proteoderm, Inc., have entered into a renewable three-year contract. This definitive agreement is a follow up of a letter of intent dated December 15, 2008 with two China-based companies, China Biopharma, Inc. and Sinoquest Investment Limited, for the exclusive license, ingredient purchase, sale and distribution of Proteoderm's stem cell-derived cosmeceutical product lines in China, Hong Kong and Taiwan... |
|
| Read Full Story > |
|
 |
| January 15, 2009 |
Proteonomix |
|
International Business Times announces Proteonomix, Inc.(PROT) is "One to Watch" |
|
Headquartered in Mountainside, New Jersey, Proteonomix Inc. is a biotechnology company trading on the Pink Sheets. Their corporate focus is on developing therapeutics based upon the use of human cells and their derivatives. The Company is developing proteins and cell therapies to treat a wide range of diseases. Proteonomix Inc. has facilities at several academic institutions... |
|
| Read Full Story > |
|
 |
| January 05, 2009 |
Proteonomix |
|
Proteonomix, Inc.(PROT) announces the appointment of Steven Byle to its Board of Directors effective January 15, 2009. |
|
Mr. Byle is a successful entrepreneur, engineer and patent attorney with a track record in domestic and international industry. He is presently Vice-President of Technology for Dockwise, B.V., a public, international company with nearly $500 million in annual revenue in the energy industry where he is charge of its R& D program and intellectual property portfolio. He has studied and taught in China and speaks fluent Chinese... |
|
| Read Full Story > |
|
 |
| December 15, 2008 |
Proteonomix |
|
Proteonomix, Inc. Announces the Publication of Research on Use of Umbilical Cord Blood in Growing Undifferentiated Embryonic Stem Cells |
|
Proteonomix, Inc. Announces the Publication of Research on Use of Umbilical Cord Blood in Growing Undifferentiated Embryonic Stem Cells. (PDF IS MISSING) |
|
| Read Full Story > |
|
 |
| December 08, 2008 |
Proteonomix |
|
Subsidiary, Proteoderm, Inc., Has Entered Into a Letter of Intent With Sinoquest Investment Limited for the Licensing, Purchase and Distribution of Proteoderm's Co. |
|
Proteonomix, Inc. (PINKSHEETS: PROT) announces the publication in Cloning and Stem Cells Journal Volume 10 No. 4, published on November 20, 2008 by Mary Ann Liebert, Inc., of an article entitled "Cells Derived from Human Umbilical Cord Blood Support the Long-Term Growth of Undifferentiated Human Embryonic Stem Cells." |
|
| Read Full Story > |
|
<< Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | Next >> |
|
